Andy Studna

5 days ago | appliedclinicaltrialsonline.com | Don Tracy |Andy Studna

June 3, 2025By In this video interview, Ron Lanton, partner, Lanton Law, highlights how tariffs on active pharmaceutical ingredients could affect resources for maintaining and accelerating R&D pipelines. In a recent video interview with Applied Clinical Trials, Ron Lanton, partner, Lanton Law, discussed the impact of drug cost increases on clinical research, predicting a reduction in government-sponsored trials due to higher R&D costs and potential funding cuts.

6 days ago | appliedclinicaltrialsonline.com | Andy Studna

Key takeawaysEnhertu plus pertuzumab showed a 44% reduction in disease progression or death versus the current standard-of-care THP regimen. The combination therapy achieved a median PFS of 40.7 months, setting a new potential first-line standard for HER2-positive metastatic breast cancer. DESTINY-Breast09 highlights efficient trial execution across global sites, emphasizing the importance of well-structured multicenter design in oncology trials.

6 days ago | appliedclinicaltrialsonline.com | Don Tracy |Andy Studna

June 2, 2025By In this video interview, Ron Lanton, partner, Lanton Law, talks FDA layoffs and their impact on inspections and clinical trial timelines. In a recent video interview with Applied Clinical Trials, Ron Lanton, partner, Lanton Law, discussed the impact of drug cost increases on clinical research, predicting a reduction in government-sponsored trials due to higher R&D costs and potential funding cuts.

1 week ago | appliedclinicaltrialsonline.com | Don Tracy |Andy Studna

May 30, 2025By In this video interview, Ron Lanton, partner, Lanton Law, discusses how a potential increase in drug costs could affect the clinical research industry. In a recent video interview with Applied Clinical Trials, Ron Lanton, partner, Lanton Law, discussed the impact of drug cost increases on clinical research, predicting a reduction in government-sponsored trials due to higher R&D costs and potential funding cuts.

1 week ago | appliedclinicaltrialsonline.com | Andy Studna

Key takeawaysEarly-phase trial design should anticipate combination therapy pathways, as seen with MK-1084 across multiple arms. Safety and tolerability remain primary endpoints, even when exploring novel mutation-specific therapies like KRAS G12C inhibitors. Operational planning must account for global scalability, with Phase III trials like KANDLELIT-004 aiming to enroll 600 patients worldwide.